Amundi Asset Management US’s Regenxbio RGNX Stock Holding History

Amundi Asset Management US’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,000	Closed	-$123K	–	1655
2019 Q4	$123K	Hold	3,000	–	–	﹤0.01%	1542
2019 Q3	$107K	Buy	+3,000	New	+$122K	﹤0.01%	1554

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Amundi Asset Management US's RGNX Position: Q1 2020 in Review

Amundi Asset Management US sold out of Regenxbio (RGNX) in Q1 2020, closing a stake of 3,000 shares — an estimated $123K sold.

Amundi Asset Management US first reported a position in RGNX in Q3 2019 and held it in 2 quarters. The position peaked at $123K in Q4 2019. 170 funds tracked by Wall St. Rank hold RGNX as of Q1 2020.

Amundi Asset Management US reported no remaining Regenxbio position as of Q1 2020 after selling out during the quarter.
Amundi Asset Management US sold 3,000 Regenxbio shares in Q1 2020, an estimated $123K.
Amundi Asset Management US first reported a position in Regenxbio in Q3 2019 and held it in 2 quarters.
Amundi Asset Management US's Regenxbio position peaked at $123K in Q4 2019.
170 funds tracked by Wall St. Rank held Regenxbio as of Q1 2020.

Based on Amundi Asset Management US's 13F filing for Q1 2020, filed 15 May 2020.